TG THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 13.66K shares, a 70.72% decline year-over-year.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 131.00K shares, a 2520.00% increase year-over-year.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 157.50K shares, a 81.56% increase year-over-year.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 209.15K shares, a 37.77% increase from fiscal 2024.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 151.81K shares, a 38.33% decline from fiscal 2023.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 246.16K shares, a 72.85% increase from fiscal 2022.
- TG THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 142.41K shares, a 170.26% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 13.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 302.16K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 131.00K shares 10-Q · filed 2026-05-06 | 335.15K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 157.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 209.15K shares 10-K · filed 2026-02-27 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 138.40K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 46.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 173.71K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 5.00K shares 10-Q · filed 2026-05-06 | 154.31K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 86.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 151.81K shares 10-K · filed 2026-02-27 |
| 2024-09-30 | 35.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 65.06K shares derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | 27.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | |
| 2024-03-31 | 2.50K shares 10-Q · filed 2025-05-09 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 246.16K shares 10-K · filed 2026-02-27 |
| 2022-12-31 | 142.41K shares 10-K · filed 2025-03-03 | |
| 2021-12-31 | 52.69K shares 10-K · filed 2024-02-29 | |
| 2020-12-31 | 35.81K shares 10-K · filed 2023-03-01 | |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-10 | |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | |
| 2015-03-31 | 0.00 shares 10-Q · filed 2015-05-11 | 46.00K shares derived: sum of 4 quarters · filed 2015-05-11 |
| 2014-12-31 | 13.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | 46.00K shares 10-K · filed 2015-03-16 |
| 2014-09-30 | 33.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | 33.00K shares derived: sum of 4 quarters · filed 2015-03-16 |
| 2014-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-24 | 0.00 shares derived: sum of 4 quarters · filed 2015-03-16 |
| 2014-03-31 | 0.00 shares 10-Q · filed 2014-05-14 | 0.00 shares derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | 0.00 shares 10-K · filed 2015-03-16 |
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | 0.00 shares derived: sum of 4 quarters · filed 2014-03-07 |
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | 0.00 shares derived: sum of 4 quarters · filed 2014-03-07 |
| 2013-03-31 | 0.00 shares 10-Q · filed 2013-05-14 | |
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | 0.00 shares 10-K · filed 2014-03-07 |
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 | |
| 2011-12-31 | 0.00 shares 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |